Interview with Brian Eklov, CEO of Dipharma Inc., by Pharma Tech Outlook
We are proud to share the recent interview published by Pharma Tech Outlook with Brian Eklov, CEO of Dipharma Inc., the US subsidiary of Dipharma Francis.
In the feature, Brian Eklov outlines how Dipharma Inc. has evolved into a fully integrated CDMO, supporting pharma partners with end-to-end solutions in the small molecule market, from early development through clinical and up to commercial supply.
He highlights Dipharma’s commitment to agility, integration, and customer focus as the key drivers behind long-lasting collaborations and reliable outcomes.
As a third-generation, family-owned company, the Dipharma Group combines a collaborative mindset with scientific excellence and uncompromising CGMP quality standards, enabling us to build strong partnerships and provide support throughout the entire lifecycle of a molecule.
Read the full article (attached or at the following link):
https://contract-research-organization.pharmatechoutlook.com/vp/dipharma/agile,_integrated,_and_client-focused:__the_dipharma_model_for_modern_cdmo_services/
Discover how Dipharma can become your trusted CDMO partner: contact us today to discuss your next project.
Experience you can trust
For more information
Paola Clerici
Communication Manager
DIPHARMA FRANCIS S.r.l.
paola.clerici@dipharma.com
